Department of Marker Localization and Assays, Biomarker Development, Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
Dis Markers. 2013;35(5):465-74. doi: 10.1155/2013/290670. Epub 2013 Oct 2.
A novel sandwich ELISA for the quantitative and sensitive determination of IL-13 in human serum and plasma was established. The assay employs an incubation step at acidic pH, which was shown to decrease nonspecific binding and interference from IL-13 binding proteins. The assay was validated and was shown to be accurate and precise over the entire quantification range (0.59 to 68.4 pg/mL in human EDTA plasma). The validated assay was successfully applied to samples from healthy volunteers and patients with atopic seasonal rhinitis. The assay is suitable for use in clinical trials to monitor efficacy or pharmacodynamic effects of drug candidates.
建立了一种用于定量和灵敏检测人血清和血浆中 IL-13 的新型夹心 ELISA 方法。该测定法采用酸性 pH 孵育步骤,该步骤显示可降低非特异性结合和 IL-13 结合蛋白的干扰。该测定法经过验证,在整个定量范围内(人 EDTA 血浆中的 0.59 至 68.4 pg/mL)均准确且精密。验证后的测定法成功应用于来自健康志愿者和特应性季节性鼻炎患者的样本。该测定法适用于临床试验,以监测候选药物的疗效或药效学效应。